<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836263</url>
  </required_header>
  <id_info>
    <org_study_id>HEALTH-F5-2012-305495-OT1</org_study_id>
    <nct_id>NCT01836263</nct_id>
  </id_info>
  <brief_title>Prevention and Treatment of Digital Ulcers in Systemic Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>marco matucci cerinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schoen Klinik Hamburg Eilbek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florence</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis is an orphan, multiorgan disease affecting the connective tissue of the
      skin and several internal organs.

      Digital ulcers are frequent and have a major impact on the quality of life in patients with
      systemic sclerosis. The etiology of digital ulcers is complex and multifactorial and the
      principal mechanisms underlying the digital ulcers formation are ischemic, mechanic and
      inflammatory, alone or in combination, on the basis of the systemic sclerosis vasculopathy.
      Consequently, there are at least three types of DU: (i) those localized at the tips of the
      fingers and toes, mainly resulting from an ischemic process, (ii) those localized on the
      dorsal aspect of the fingers where the skin retraction due to fibrosis over bony prominences
      seems to be the main cause, and (iii) those evolving on a pitting scar or subcutaneous
      calcinosis due to a combined irritative-inflammatory mechanism. An early therapy to prevent
      or rapidly heal digital ulcers is today considered a mandatory approach to maintain quality
      of life and spare the enormous costs due to conventional digital ulcer management.

      This observational trial is part of the collaborative project &quot;DeSScipher&quot;, one out of five
      observational trials to decipher the optimal management of systemic sclerosis.

      Aim of this observational trial is:

        1. To identify the best treatment combination for prevention of digital ulcers in patients
           with fulfilment of the new ACR/EULAR SSc criteria or the preliminary VEDOSS criteria for
           very early diagnosis of systemic sclerosis

        2. To identify the best treatment associated with improved healing of digital ulcers in
           patients with fulfilment of the new ACR/EULAR SSc criteria

      Thus, the observational trial consist of a prevention arm and a healing arm.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Prevention arm: Number of new digital ulcers</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Healing arm: Time to healing of manifest digital ulcers</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevention arm: Time to development of new digital ulcers</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healing arm: Number of healed digital ulcers</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Prevention arm: novel composite digital ulcer prediction score</measure>
    <time_frame>24 months</time_frame>
    <description>Prevention: A novel composite digital ulcers prediction score which will be tested against the already proposed capillaroscopic prediction score CSURI</description>
  </other_outcome>
  <other_outcome>
    <measure>Healing arm: novel composite outcome score for the assessment of worsening of digital ulcers despite treatment</measure>
    <time_frame>24 months</time_frame>
    <description>Healing: A novel composite outcome score for the assessment of worsening of digital ulcers despite treatment</description>
  </other_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">420</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Ulcer</condition>
  <arm_group>
    <arm_group_label>Prevention arm: CCB &amp; i.v. iloprost</arm_group_label>
    <description>prevention arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevention arm: bosentan &amp; sildenafil</arm_group_label>
    <description>prevention arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healing arm: CCB &amp; i.v. iloprost</arm_group_label>
    <description>healing arm: patients receiving a combination of calcium channel blockers (CCB) and concomitant i.v. iloprost (i.v. iloprost at least in the last three months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healing arm: bosentan &amp; sildenafil</arm_group_label>
    <description>healing arm: patients receiving a combination of the endothelin receptor antagonist bosentan and the Phosphodiesterase-5 inhibitor sildenafil</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population are adult and juvenile systemic sclerosis patients from the EUSTAR
        cohort (MEDSonline database), the VEDOSS cohort and the jSScWG cohort
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Juvenile and adult patients with diagnosis of systemic sclerosis according to the
             ACR/EULAR SSc criteria or the PRES/ACR/EULAR juvenile SSc criteria for enrollment into
             the prevention and healing arm

          -  Patients with fulfilment of the preliminary criteria for very eary diagnosis of
             systemic sclerosis (VEDOSS criteria) for enrollment into the prevention arm

        Patients with active digital ulcers will be allocated into the healing arm. Patients
        without previous or history of digital ulcers (but currently without active digital ulcers)
        will be allocated into the prevention arm.

        Definition of digital ulcers (DU): DU are 1) loss of tissue, 2) DU derived from digital
        pitting scars and 3) DU derived from calcinosis.

        IN THIS STUDY WE CONSIDER ONLY DU (1) LOSS OF TISSUE. THE OTHER DU (2) and DU (3) ARE
        REGISTERED IN THE DATA BASE IF THEY ARE PRESENT, BUT ARE EXCLUDED FROM EVALUATION.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Matucci-Cerinic, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Del Galdo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulf MÃ¼ller-Ladner, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Justus-Liebig-University GieÃen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco Matucci-Cerinic, Prof.</last_name>
    <email>marco.matuccicerinic@unifi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francesco Del Galdo, Prof.</last_name>
    <email>F.DelGaldo@leeds.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UniversitÃ© Paris Descartes, HÃ´pital Cochin, Service de Rhumatologie A &amp; INSERM 1016</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yannick Allanore, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-University GieÃen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulf MÃ¼ller-Ladner, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingo H. T, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Frerix, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CharitÃ© UniversitÃ¤tsmedizin Berlin, CharitÃ© Centrum 12 fÃ¼r Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriela Riemekasten, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Pediatric Rheumatology, Klinikum Eilbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivan Foeldvari, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem - University of Pecs</name>
      <address>
        <city>Pecs</city>
        <zip>H-7622</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laszlo Czirjak, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marco Matucci-Cerinic, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico, Via Pansini</name>
      <address>
        <city>Napoli-Italia</city>
        <zip>5-80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriele Valentini, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Felix-Platter Spital, University of Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH 4012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich Walker, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Zurich, Department of Rheumatology</name>
      <address>
        <city>Zurich</city>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oliver Distler, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Del Galdo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital, University College London</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Denton, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2013</study_first_submitted>
  <study_first_submitted_qc>April 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <last_update_submitted>April 24, 2013</last_update_submitted>
  <last_update_submitted_qc>April 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Florence</investigator_affiliation>
    <investigator_full_name>marco matucci cerinic</investigator_full_name>
    <investigator_title>Prof. Marco Matucci-Cerinic</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Iloprost</mesh_term>
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
    <mesh_term>Bosentan</mesh_term>
    <mesh_term>Endothelin Receptor Antagonists</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

